Clinical trials: MLH1 Gene Mutation
BRCA1 Mutation, POLD1 Gene Mutation
An Intervention to Increase Genetic Testing in Families Who May Share a Gene Mutation Related to Cancer Risk and An Intervention to Help Patients and Their Primary Care Providers Stay Up-to-date About Uncertain Genetic Test Results
The purpose of this study is to examine the impact of new cancer genetic counseling models that aim to increase patient engagement with the genetics team.
- Conditions
- BRCA1 Mutation, POLD1 Gene Mutation, CDKN2A Mutation, BRCA2 Mutation
- Trial name
- NCT05420064
- Testing
- Intervention Arm At-risk Relative/ARR Contacts, MyGene Portal, Standard of Care
- Where
- 8 sites in United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Memorial Sloan Kettering Cancer Center
BARD1 Gene Mutation, BRCA1 Gene Mutation
Stand up to Cancer: MAGENTA (Making Genetic Testing Accessible)
This randomized clinical trial studies how well online genetics educational video with or without pre- and/or post-telephone genetics counseling works in assessing cancer-risk distress in patients with triple negative breast…
- Conditions
- BARD1 Gene Mutation, BRCA1 Gene Mutation, BRCA2 Gene Mutation, BRIP1 Gene Mutation
- Trial name
- NCT02993068
- Testing
- Educational Intervention, Genetic Counseling, Laboratory Biomarker Analysis
- Where
- 2 sites in United States
- Volunteers
- 5,200 people
- Sponsor
- M.D. Anderson Cancer Center
Gastrectomy for Gastric Cancer, Gastrectomy
How Epigenetic Changes in hMLH1 Connect Lab Research With Diagnosis in Gastric Cancer
DNA methylation is one of the key mechanisms that are thought to underlie the association between aging and cancer. Several methylation-based measures of biological aging have been developed and have demonstrated an association…
- Conditions
- Gastrectomy for Gastric Cancer, Gastrectomy, MLH1 Gene Mutation, Gastric Cancer
- Trial name
- EMBRACE-hGC (NCT06982768)
- Where
- Italy
- Volunteers
- 245 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Deleterious BARD1 Gene Mutation, Deleterious BRCA1 Gene Mutation
Surgery in Preventing Ovarian Cancer in Patients With Genetic Mutations
This phase II trial studies how well surgery works in preventing ovarian cancer in patients with genetic mutations at risk of ovarian cancer.
- Conditions
- Deleterious BARD1 Gene Mutation, Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation, Deleterious BRIP1 Gene Mutation
- Trial name
- NCT02760849
- Testing
- Laboratory Biomarker Analysis, Oophorectomy, Quality-of-Life Assessment
- Where
- 9 sites in United States
- Volunteers
- 374 people
- Sponsor
- M.D. Anderson Cancer Center
BRCA-Mutated Ovarian Carcinoma, BRIP1 Gene Mutation
Cascade Testing in Families With Newly Diagnosed Hereditary Breast and Ovarian Cancer Syndrome
Identification of BRCA mutations in ovarian cancer patients may help guide cancer therapies, prognosis, post-operative screening, and other preventative treatments beyond the initial diagnosis.
- Conditions
- BRCA-Mutated Ovarian Carcinoma, BRIP1 Gene Mutation, MSH2 A636P, MLH1 Gene Mutation
- Trial name
- NCT04009148
- Testing
- CASCADE genetic screening
- Where
- United States
- Volunteers
- 118 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Lynch Syndrome, Lynch Syndrome I
Lynch Syndrome X-Talk of Enteral Mucosa With Immune System
Lynch syndrome (OMIM #120435) is the most common dominantly inherited colorectal cancer syndrome with an estimated prevalence of 1:270 individuals.
- Conditions
- Lynch Syndrome, Lynch Syndrome I, Lynch Syndrome II, Lynch Syndrome I (Site-specific Colonic Cancer)
- Trial name
- LYNX-EYE (NCT06708429)
- Testing
- LYNX EYE (Lynch syndrome X-Talk of Enteral mucosa with Immune System)
- Where
- 5 sites in United States, Italy
- Volunteers
- 300 people
- Sponsor
- San Raffaele University
Lynch Syndrome, Lynch Syndrome I
Videocapsule Endoscopy in Lynch Syndrome
Background Lynch syndrome is caused by a pathogenic variant in one of the four Mismatch Repair genes (MMR): MLH1, MSH2/Epcam, MSH6, or PMS2.
- Conditions
- Lynch Syndrome, Lynch Syndrome I, Lynch Syndrome II, MLH1 Gene Mutation
- Trial name
- NCT05704010
- Testing
- Video capsule endoscopy
- Where
- Italy
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- San Raffaele University
Colorectal Cancer, Adenoma Colon
Liquid Biopsy and Machine Learning for Early Colorectal Cancer, Adenomas, Lynch Cancers, and Residual Disease Detection
This is an multicenter study that will test the diagnostic accuracy of a blood test (i.e., a liquid biopsy) for the diagnosis of colorectal cancer (CRC), advanced adenomas (AAs), as well as Lynch-syndrome associated cancers.
- Conditions
- Colorectal Cancer, Adenoma Colon, Adenoma Colon Polyp, Colon Adenoma
- Trial name
- BEACON (NCT07450612)
- Testing
- BEACON
- Where
- 4 sites in Italy
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- San Raffaele University
Colon Adenoma, Colon Carcinoma
Nivolumab in Preventing Colon Adenomas in Participants With Lynch Syndrome and a History of Partial Colectomy
This phase II trial studies how well nivolumab works in preventing colon adenomas in participants with Lynch syndrome and a history of surgery to remove part of the colon.
- Conditions
- Colon Adenoma, Colon Carcinoma, Lynch Syndrome, MLH1 Gene Mutation
- Trial name
- NCT03631641
- Testing
- Nivolumab
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- John Hays
Colorectal Cancer, APC Gene Mutation
Patogenic Mutation in 5 Genes
This is a pathogenic mutation profile of colorectal patients specifically in 5 genes, i.e. APC, TP53, PIK3CA, KRAS, and MLH1. Single nucleotide variants identified were synchronized with patients' characteristics.
- Conditions
- Colorectal Cancer, APC Gene Mutation, TP53 Gene Mutation, PIK3CA Gene Mutation
- Trial name
- NCT04976439
- Testing
- co-occuring mutation
- Where
- Indonesia
- Volunteers
- 22 people
- Sponsor
- Dr Cipto Mangunkusumo General Hospital
Metastatic Carcinoma in the Liver, MLH1 Gene Mutation
Durvalumab and Tremelimumab in Treating Patients With Microsatellite Stable Metastatic Colorectal Cancer to the Liver
This pilot clinical trial studies the side effects and how well durvalumab and tremelimumab work in treating patients with microsatellite stable colorectal cancer that has spread to the liver.
- Conditions
- Metastatic Carcinoma in the Liver, MLH1 Gene Mutation, MSH6 Gene Mutation, PMS2 Gene Mutation
- Trial name
- NCT03005002
- Testing
- Durvalumab, Laboratory Biomarker Analysis, Tremelimumab
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- City of Hope Medical Center